Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Invasive Fungal Infections While on Voriconazole, Liposomal Amphotericin B, or Micafungin for Antifungal Prophylaxis in Pediatric Stem Cell Transplant Patients.

Bui A, Nguyen V, Hsu C, Hyde B, Simms-Waldrip T.

J Pediatr Pharmacol Ther. 2019 May-Jun;24(3):220-226. doi: 10.5863/1551-6776-24.3.220.

2.

Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.

Park S, Kim K, Jang JH, Kim SJ, Kim WS, Chung DR, Kang CI, Peck KR, Jung CW.

J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7.

PMID:
27394404
3.
4.

Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.

Morello E, Pagani L, Coser P, Cavattoni I, Cortelazzo S, Casini M, Billio A, Rossi G.

Bone Marrow Transplant. 2011 Jan;46(1):132-6. doi: 10.1038/bmt.2010.76. Epub 2010 Apr 12.

PMID:
20383205
5.

Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.

Luu Tran H, Mahmoudjafari Z, Rockey M, Henry D, Grauer D, Aljitawi O, Abhyankar S, Ganguly S, Lin T, McGuirk J.

J Oncol Pharm Pract. 2016 Apr;22(2):228-34. doi: 10.1177/1078155214560920. Epub 2014 Dec 3.

6.

Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.

Ziakas PD, Kourbeti IS, Mylonakis E.

Clin Ther. 2014 Feb 1;36(2):292-306.e1. doi: 10.1016/j.clinthera.2013.11.010. Epub 2014 Jan 17.

PMID:
24439393
7.

Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.

Maximova N, Schillani G, Simeone R, Maestro A, Zanon D.

Adv Ther. 2017 May;34(5):1184-1199. doi: 10.1007/s12325-017-0534-7. Epub 2017 Apr 20.

PMID:
28429246
8.

EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.

Llinares P, Ruiz I, Zaragoza R, Ferrer R, Rodríguez AH, Maseda E, Grau S; EPICO PROJECT GROUP.

Rev Iberoam Micol. 2016 Oct - Dec;33(4):206-215. doi: 10.1016/j.riam.2016.06.002. Epub 2016 Oct 15. Erratum in: Rev Iberoam Micol. 2017 Jan - Mar;34(1):62.

PMID:
27751781
9.

Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.

Gomes MZ, Mulanovich VE, Jiang Y, Lewis RE, Kontoyiannis DP.

Antimicrob Agents Chemother. 2014;58(2):865-73. doi: 10.1128/AAC.01525-13. Epub 2013 Nov 25.

10.

Cost-effectiveness analysis of voriconazole, fluconazole, and amphotericin B for invasive fungal infections following allogeneic hematopoietic stem cell transplantation in Mexico.

Morfín-Otero R, Alvarado-Ibarra M, Rodriguez-Noriega E, Resendiz-Sanchez J, Patel DA, Stephens JM, Di Fusco M, Mendoza CF, Charbonneau C.

Clinicoecon Outcomes Res. 2018 Sep 6;10:511-520. doi: 10.2147/CEOR.S157642. eCollection 2018.

11.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
12.

Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis.

Döring M, Hartmann U, Erbacher A, Lang P, Handgretinger R, Müller I.

BMC Infect Dis. 2012 Jul 2;12:151.

13.

Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.

Shehab N, DePestel DD, Mackler ER, Collins CD, Welch K, Erba HP.

Pharmacotherapy. 2007 Jul;27(7):970-9.

14.

Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.

Mandhaniya S, Swaroop C, Thulkar S, Vishnubhatla S, Kabra SK, Xess I, Bakhshi S.

J Pediatr Hematol Oncol. 2011 Dec;33(8):e333-41. doi: 10.1097/MPH.0b013e3182331bc7.

PMID:
22042283
15.

Invasive Fungal Infection after Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis.

Baker AW, Maziarz EK, Arnold CJ, Johnson MD, Workman AD, Reynolds JM, Perfect JR, Alexander BD.

Clin Infect Dis. 2019 Feb 25. pii: ciz156. doi: 10.1093/cid/ciz156. [Epub ahead of print]

PMID:
30801642
16.

Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice.

Langebrake C, Rohde H, Lellek H, Wolschke C, Kröger NM.

Clin Transplant. 2014 Mar;28(3):286-91. doi: 10.1111/ctr.12310. Epub 2014 Jan 30.

PMID:
24479680
17.

Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients.

Tamura K, Drew R.

Drugs Today (Barc). 2008 Jul;44(7):515-30. doi: 10.1358/dot.2008.44.7.1230943. Review.

PMID:
18806902
18.

Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.

Strasfeld L, Weinstock DM.

Expert Rev Anti Infect Ther. 2006 Jun;4(3):457-68. Review.

PMID:
16771622
19.

Comparative effectiveness of antifungal agents in patients with hematopoietic stem cell transplantation: a systematic review and network meta-analysis.

Su HC, Hua YM, Feng IJ, Wu HC.

Infect Drug Resist. 2019 May 15;12:1311-1324. doi: 10.2147/IDR.S203579. eCollection 2019.

Supplemental Content

Support Center